Evariant Stock

evariant.comHealthcare / Other HealthcareFounded: 2008Funding to Date: $89.77MM

Evariant is a provider of marketing solutions that enable providers to optimize growth through smarter consumer acquisition, patient retention, and network utilization strategies through healthcare’s only Patients for Life Platform.

Register for Details

For more details on financing and valuation for Evariant, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Evariant.

Register Today

Team

Management Team

Clay Ritchey
Chief Executive Officer & Board Member
Rob Grant
Executive Vice President & Co-Founder & Board Member
Andrew Keenan
Chief Financial Officer
Nick Bequary
Chief Technology Officer
William Moschella
Co-Founder, Board Member & Chairman
Frederick Constantineau
Chief Operating Officer

Board Members

Jason Kreuziger
The Goldman Sachs Group
David Chen Ph.D
Lightspeed Venture Partners
William Moschella
Marcel Gamache
David Tamburri
Health Enterprise Partners
Thomas Rodgers
Christopher Schaepe
Lightspeed Venture Partners
Ezra Mehlman
Health Enterprise Partners
Clay Ritchey

Other companies like Evariant in the Other Healthcare sector

Sector
Last Round Est. Valuation
$165MM
Sector
Last Round Est. Valuation
$368.08MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$125MM
Sector
Last Round Est. Valuation
$140MM
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$173.59MM
Sector
Last Round Est. Valuation
$300.91MM

News Highlights

Evariant Raises Additional Funding in Series C Round |FinSMEs
Evariant, a Farmington, Conn.-based provider of a healthcare CRM and analytics solution built on Salesforce, secured additional funding as part of their Series C round. Backers included McKesson Ventures and Salesforce Ventures, which joined existing investors Health Enterprise Partners, Lightspeed Venture Partners, and Goldman, Sachs & Co. The company intends to use the funds to …
Updated on: Sep 24, 2023